1 / 47

Management of Atrial Fibrillation in Heart Failure

Management of Atrial Fibrillation in Heart Failure. Maximo Rivero-Ayerza M.D. Clinical Electrophysiology Ziekenhuis Oost Limburg, Genk. Objectives. Assess the relation between AF and HF Try to establish the optimal treatment strategy. Prevalence.

rory
Download Presentation

Management of Atrial Fibrillation in Heart Failure

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Management of Atrial Fibrillation in Heart Failure Maximo Rivero-Ayerza M.D. Clinical Electrophysiology Ziekenhuis Oost Limburg, Genk

  2. Objectives • Assess the relation between AF and HF • Try to establish the optimal treatment strategy

  3. Prevalence Unadjusted cumulative incidence of first AF after Heart Failure - Framingham Study ↑ Mortality in AF: - Men HR 1.6 - Women HR 2.7 20% of patients with HF develop AF within 4 years Wang, T. J. et al. Circulation 2003;107:2920-2925

  4. Prevalence Concomitant HF: 13 % age 35 – 64 yrs 21% age > 65 yrs Wattigneyet al. Circulation 2003;108:711-716

  5. Prevalence % Patients with Atrial Fibrillation prevalence increases with severity of heart failure Class I – II Class III - IV

  6. Relation between AF and HF

  7. Substrate Atrial Fibrillation Triggers

  8. AF – Atrial remodeling • CHF induced followed by 5 weeks of recovery • Irreversible induction of fibrosis and conduction abnormalities. • Duration of AF was reduced in parallel to LA function. Shinagawa, K. et al. Circulation 2002;105:2672-2678

  9. Effect of intra-atrial pressure on AF 5 cm H2O 18 cm H2O Increases in intra-atrial pressure increases the rate of the dominant frequency at the level of the PV junction compared to LA free wall Kalifa et al. Circulation. 2003;108:668.

  10. Effect of intra-atrial pressure on AF Increases in intra-atrial pressure increases the number of waves (rotors) emanating from the PVs Kalifa et al. Circulation. 2003;108:668.

  11. Types of AF Triggers ectopic foci Paroxysmal AF Electrophysiologic Remodeling Chronic Substrate fibrosis Persistent AF Permanent AF Stambler et al JCE 2003;14:499Li, Nattel et al. Circulation. 1999;100:87-95

  12. AF – Hemodynamic Effects *p < 0.01 N=16 Cardiac Output (L/Min) Cardiac Output (L/Min) NSR AF VVI VVI VVT 60 AVG VVI -AVG VVT Clark DM. JACC 1997; 30:1039-45

  13. 200 Failing Nonfailing 100 % change in Force 0 20 60 120 180 Heart Rate (beats / min) Effects of AF in HF Rapid heart rates depress contractility: abnormal force - frequency relationship in heart failure Mulieri Circulation 1992;

  14. Effects of AF in HF 344 HF pts FU= 19± 12 months • Development of AF (28 pts): • NYHA worsened (2.4 to 2.9) • Peak O2 consumption declined • (16 to 11 ml/kg/min) • CI decreased (2.2 to 1.8) • Mitral regurgitation increased • (1.8 to 2.4) Pozolli et al. JACC 1998;31(1):197-204.

  15. Prognostic significanse of AF CHARM N= 7601 pts (15% with AF) Age= 65 y Baseline AF HR 1.38 (low EF) HR 1.80 (PEF) New onset AF HR 2.57 (PEF) HR 1.85 (low EF) J Am Coll Cardiol 2006;47:1997

  16. Prognostic significanse of AF COMMET N= 3029 pts (20% with AF) Age= 62 y Baseline AF RR=1.29 (univariate) Baseline AF predictive of HF hosp. New Onset AF RR=1.90 (multivariate) Eur Heart J 2005;26:1303

  17. Prognostic significanse of AF DIG N= 6800 pts (11% SVT) Age= 63 y RR= 2.45 CHEST 2000;118:914

  18. Prognostic significanse of AF Epidemiological • As many AF pts developed HF as HF pts developed AF. • New AF in CHF individuals was associated with increased mortality • Antecedent AF was not predictive of mortality in CHF pts. Wang TJ. Et al Circulation. 2003;107:2920

  19. No AF Previous AF New onset AF EuroHeart Failure - Mortality P < 0.001 P < 0.001 7% 7% 12 % 13 % 13 % 19 % Rivero-Ayerza et al. submitted EHS-HF EHS-HF

  20. Independent predictors of hospital mortality Multiple logistic regression analysis Less likely to die More likely to die 1.5 (1.1-2.0) New Onset AF Previous AF Age Male Gender Rapid AF LA Dilatation 50% EF  ACS VHD Renal Failure Stroke Elevated BP 0.1 1 10 OR (95%CI) Rivero-Ayerza et al. submitted EHS-HF

  21. AF and HF Summary • AF and HF tend to coexist and share predisposing factors • One may directly predispose to the other • The combination of both is believed to carry a worse • prognosis then either alone. • In the setting of HF onset of AF seems to be a stronger • predictor of adverse outcome irrespective of LV function

  22. Management of AF in HF Objectives • Prevention of AF would be ideal • Avoiding hemodynamicdeterioration • and improvingsymptoms • 3. Preventing stroke

  23. Role of ACEI and ARB’s in prevention of AF 177 pts parox AF End point: recurrence of AF Randomized - Amiodarone (41 % recurrence) - Amio + losartan (19% recurrence) - Amio + perindopril (24 % rec.) Yuehui et al. EHJ 2006;27:1841

  24. ACE inhibition reduces atrial fibrosis in a heart failure model Control 5 Weeks 5 Weeks +Enalapril Li, Nattel, et al Circulation. 2001; 104: 2608

  25. Role of ACEI and ARB’s in prevention of AF • 56,308 patients (11 studies) • Overall RR reduction of 28% • Benefit is similar for ACEI or • ARBs • RRreduction 44% in HF Healey J, Baranchuk A, et al JACC 2005;45:1832

  26. Prevention of AF - Statins Recurrence after cardioversion of lone persistent AF Antiinflammatory effect ? / Antioxidant effect ? / Antiarrhythmic effect ? Siu et al. Am J Cardiol 2003; 92:1343 // Shiroshita-Takeshita et al. Circulation. 2004;110:2313-2319.

  27. Rate vs Rhythm control Rhythm Control Rate Control • Improve symptoms • Improve functional capacity • Lower risk of stroke • Avoid anticoagulation • Improve survival • Improve symptoms • Avoid side effects of AAD • Avoid pro-arrhythmia

  28. Rate vs Rhythm control Vidaillet et al. Curr Opin Cardiol 20:15 // Testa et al. EHJ. 2005

  29. AFFIRM • 4060 patients • No survival benefit (23.8% vs 21.3%) • 23 % Prior HF • Mean EF 55% • Normal EF 74 % NEJM 2002;347:1825

  30. AFFIRM NYHA 6’ walk - SR improved survival - AAD increased (non-cardiac) mortality - Improved FC JACC 2005;46:1891 / NEJM 2002;347:1825

  31. RACE Sub-study HF • Rate control is not inferior to rhythm • If SR is maintained prognosis may improve (more CV death, HF hospitalizations and Bleeding) Hagens et al. Am Heart J 2005;149:1106

  32. DIAMOND • 506 pts with LV dysfunction • Randomized to Dofetilide or Placebo • No effect on mortality • Effect of SR on mortality RR 0.44 (0.30-0.64) Survival according to rhythm Survival according to Rx Pedersen et al. Circulation 2001;104:292

  33. Management of AF in HR SAFE T (persistent AF) CTAF Amiodarone has proven to be safe in HF and CAD patients NEJM 2000;342:913 / NEJM 2005;352:18

  34. Management of AF in HR Fuster, V. et al. Circulation 2006;114:e257-e354

  35. Management of AF in HR In HF patchy fibrosis tends to accumulate at or near PV ostia Jaliffe et al. HRS 2007

  36. AF ablation

  37. AF ablation RSPV

  38. Management of AF in HF • 58 pts • HF and LVEF <45% • FU= 12±7 m • SR in 69 % at 12 months • LVEF improved 21±13 % • Improved exercise capacity, • symptoms, and QOL NEJM 2004:351;23

  39. Relation between AF and HF Ablation Neurohormonal/ Anti-inflammatory

  40. Management of AF and HF NYHA II-IV and EF < 35% NYHA I and HF hosp or EF <25%

  41. Management of AF in HR Tachycardia Induced Cardiomyopathy - Cardiomyopathy can be caused by any tachycardia (>110 bpm) that occurs as little as 10-15% of day - Severity related to rate and duration of  HR - Maximal improvement after rate control may require up to 8 months - After improvement susceptibility to rapid deterioration remains if tachycardia recurs Olshansky et al Circulation 2004 Fenelon et al PACE 1996; 19:95-106 Shinbane J et al. JACC 1997; 29: 709-715

  42. Management of AF in HR AV junction ablation and Pacemaker Implantation Advantages: • Rate control without drugs • Regularizes ventricular rate Disadvantages • Requires permanent pacemaker • Fibrillation continues • Risk of torsade de pointes • Risk of hemodynamic deterioration (RV pacing) Ozcan et al. NEJM 2001;344:1043

  43. Management of AF in HF Favor rhythm control • First or infrequent episodes of persistent AF • Significant symptoms in AF • Difficult rate control • Contraindication to long term warfarin Favor rate control • Asymptomatic in atrial fibrillation • Contraindication to amiodarone

  44. Antithrombotic Therapy Risk of stroke 6% / y (5 - 6 fold increase) Warfarin (INR 2.0 - 2.6): • 62% reduction (CI 48% - 72%) • 37 NNT to prevent 1 stroke • major hemorrhage: 0.6% / yr • 20% discontinue anticoagulation Aspirin (25 mg - 1300 mg/day) • 22% reduction (2% - 38%) Hart et al. Ann Intern Med 1999;131:492

  45. Antithrombotic Therapy CHADS² CHADS Stroke rate Score 1 2.8 %/y Score 2 4.0 %/y Score 3 5.9 %/y Score 4 8.5 %/y Score 5 12.5 %/y Score 6 18.2 %/y • Congestive HF • Hypertension • Age >75 • Diabetes • Previos stroke (2 points) Gage et al. JAMA 2001;285:2864

  46. Summary • AF and HF are not only clinically associated but are • physiopatologically inter-related • AF seems to be a prognostic indicator (certainly recent onset AF) • irrespective of LV performance. • Consequently prevention of AF should carry a better prognosis • Although no benefit of rhythm vs rate control has been shown. • Data suggest that certain subgroup of patients will benefit from SR • Irrespective of management strategy, antithrombotic Rx is • warranted

  47. Conclusion “I have been poor and I have been rich. Rich is better.” Attributed to Sophie Tucker

More Related